FI92196B - Förfarande för framställning av terapeutiskt användbara 2-pyridoner - Google Patents

Förfarande för framställning av terapeutiskt användbara 2-pyridoner Download PDF

Info

Publication number
FI92196B
FI92196B FI895925A FI895925A FI92196B FI 92196 B FI92196 B FI 92196B FI 895925 A FI895925 A FI 895925A FI 895925 A FI895925 A FI 895925A FI 92196 B FI92196 B FI 92196B
Authority
FI
Finland
Prior art keywords
alkyl
optionally substituted
branched
methyl
mmol
Prior art date
Application number
FI895925A
Other languages
English (en)
Finnish (fi)
Other versions
FI92196C (sv
FI895925A0 (sv
Inventor
Rolf Angerbauer
Peter Fey
Walter Huebsch
Thomas Philipps
Hilmar Bischoff
Dieter Petzinna
Delf Schmidt
Guenter Thomas
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3841991A external-priority patent/DE3841991A1/de
Priority claimed from IT8920861A external-priority patent/IT8920861A0/it
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI895925A0 publication Critical patent/FI895925A0/sv
Application granted granted Critical
Publication of FI92196B publication Critical patent/FI92196B/sv
Publication of FI92196C publication Critical patent/FI92196C/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Claims (9)

1 Jl dx) °Yii 30 (ΛΛβ E jossa A, B, D ja E merkitsevät samaa kuin edellä, annetaan rea-35 goida inerteissä liuottimissa emästen läsnä ollessa aset- 921 96 58 etikkaesterin kanssa, jolla on yleinen kaava (X) O Il g H3C-C-CH2-COOR (X) 5 jossa R9 merkitsee samaa kuin edellä. Il 59 >'2ί>6
1. Förfarande för framställning av terapeutiskt användbara 2-pyridoner och salter av dessa med den allmän-5 na formeln (I), OH OH Jl JL .coor9 0*^ E väri A Sr fenyl, som eventuellt är substituerad med fluor;
15 B är C3-C6-cykloalkyl eller rakkedjad eller förgrenad 03-C4-alkyl; D är väte eller rakkedjad eller förgrenad C^-C^-alkyl, som eventuellt är substituerad med en grupp -OR4, varvid R4 är väte, rakkedjad eller förgrenad, eventuellt med fenyl 20 substituerad Cj-C^alkyl eller trialkylsilyl, varvid i alkylgruppen kan ingä upptill sex kolatomer; E är rakkedjad eller förgrenad C^-C^-alkyl, som eventuellt är substituerad med fenyl eller metoxifenyl; och 25 R9 är väte, rakkedad eller förgrenad Cj-C^-alkyl, eller natrium- eller kaliumjon, kännetecknat därav, att man reducerar ketoner med den allmänna formeln (VIII) 0H $ o JL Jl C00R3
30 A (1^^ D IJ1 (Vili) 0-^ B E 35 väri so η\ϊβ A, Β, D och E betecknar sanuna som ovan, och R9 är alkyl, och vid framställning av syror förtvälas estrarna, och vid framställning av salter förtvälas estrarna, och 5 eventuellt separeras isomererna.
2. Ketoner med den allmänna formeln (VIII) 0H 3 Q II COORy 10. jl (VIII) E 15 vari A är fenyl, som eventuellt är substituerad med fluor; B är C3-C6-cykloalkyl eller rakkedjad eller förgrenad Cx-C4-alkyl; D är väte eller rakkedjad eller förgrenad C1-C4-alkyl, som 20 eventuellt är substituerad med en grupp -OR4, varvid R4 är väte, rakkedjad eller förgrenad, eventuellt med fenyl substituerad C1-C4-alkyl, eller trialkylsilyl, varvid i alkylgruppen kan ingä upptill sex kolatomer;
25 E är rakkedjad eller förgrenad C^-C^-alkyl, som eventuellt är substituerad med fenyl eller metoxifenyl; och R9 är alkyl.
3. Förfarande för framställning av ketoner med den allmänna formeln (VIII) 30 XJOcoor9 »JJ1 <VIII)
35. X E II 61 92! >'6 väri A är fenyl, som eventuellt är substituerad med fluor; B är C3-C6-cykloalkyl eller rakkedjad eller förgrenad Cx-C4-alkyl;
5 D är väte eller rakkedjad eller förgrenad Cx-C4-alkyl, som eventuellt är substituerad med en grupp -OR4, varvid R4 är väte, rakkedjad eller förgrenad, eventuellt med fenyl substituerad Cj-C^-alkyl eller trialkylsilyl, varvid i alkylgruppen kan ingä upptill sex 10 kolatomer; E är rakkedjad eller förgrenad Cj-C^-alkyl, som eventuellt är substituerad med fenyl eller metoxifenyl; och R9 är alkyl, kännetecknat därav, att aldehyder med den allmänna formeln (IX) 15 0 a (i"11 X J1 <IX> ΌΎ\\ 20 „ E väri A, B, D och E betecknar samma som ovan fär reagera i ett 25 inert lösningsmedel i närvaro av en bas med acetättikaes-ter med den allmänna formeln (X) O Il 9 h3c-c-ch2-coor (X) 30 väri R9 betecknar samma som ovan.
FI895925A 1988-12-14 1989-12-12 Förfarande för framställning av terapeutiskt användbara 2-pyridoner FI92196C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3841991 1988-12-14
DE3841991A DE3841991A1 (de) 1988-12-14 1988-12-14 Substituierte 2-pyridone und pyrid-2-thione, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
IT2086189 1989-06-13
IT8920861A IT8920861A0 (it) 1989-06-13 1989-06-13 2 pirodoni e pirid 2 tioni sostituiti, processo per produrli e loro impiego in medicinali.

Publications (3)

Publication Number Publication Date
FI895925A0 FI895925A0 (sv) 1989-12-12
FI92196B true FI92196B (sv) 1994-06-30
FI92196C FI92196C (sv) 1994-10-10

Family

ID=25875117

Family Applications (1)

Application Number Title Priority Date Filing Date
FI895925A FI92196C (sv) 1988-12-14 1989-12-12 Förfarande för framställning av terapeutiskt användbara 2-pyridoner

Country Status (16)

Country Link
US (1) US5032602A (sv)
EP (1) EP0373423B1 (sv)
JP (1) JP2954954B2 (sv)
CN (1) CN1032203C (sv)
AT (1) ATE100086T1 (sv)
CA (1) CA2005206A1 (sv)
DE (1) DE58906708D1 (sv)
DK (1) DK630489A (sv)
ES (1) ES2061902T3 (sv)
FI (1) FI92196C (sv)
HU (2) HUT59907A (sv)
IE (1) IE63401B1 (sv)
IL (1) IL92632A0 (sv)
NO (1) NO176476C (sv)
NZ (1) NZ231707A (sv)
PT (1) PT92550B (sv)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238576A (en) * 1990-06-18 1994-12-22 Merck & Co Inc Pyridinone derivatives, preparation and pharmaceutical compositions thereof
US5308854A (en) * 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100705519B1 (ko) * 2002-02-14 2007-04-10 파마시아 코포레이션 P38 map 키나제의 조절제로서의 치환된 피리디논
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
UA100126C2 (en) 2007-09-14 2012-11-26 Аддекс Фарма С.А. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
PT2200985E (pt) 2007-09-14 2011-07-21 Ortho Mcneil Janssen Pharm 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,2,4―트리아졸로[4,3―a]피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
MX2016009471A (es) 2014-01-21 2016-10-13 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso.
US10160718B2 (en) 2015-12-22 2018-12-25 Eastman Chemical Company Methods of making compounds having antidegradant and antifatigue efficacy
US10287418B2 (en) 2015-12-22 2019-05-14 Eastman Chemical Company Compounds with antidegradant and antifatigue efficacy and compositions including said compounds
US10167252B2 (en) 2015-12-22 2019-01-01 Eastman Chemical Company Compounds and mixtures with antidegradant and antifatigue efficacy and compositions including such compounds
US10260017B2 (en) 2015-12-22 2019-04-16 Eastman Chemical Company Compounds and mixtures with antidegradant and antifatigue efficacy and compositions including said compounds
US10428009B2 (en) * 2015-12-22 2019-10-01 Eastman Chemical Company Methods of making compounds and mixtures having antidegradant and antifatigue efficacy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758759A (fr) * 1969-11-12 1971-05-10 Merck & Co Inc Pyridones anti-inflammatoires

Also Published As

Publication number Publication date
PT92550B (pt) 1996-06-28
ES2061902T3 (es) 1994-12-16
US5032602A (en) 1991-07-16
CA2005206A1 (en) 1990-06-14
NZ231707A (en) 1992-06-25
IE63401B1 (en) 1995-04-19
EP0373423A1 (de) 1990-06-20
DK630489D0 (da) 1989-12-13
FI92196C (sv) 1994-10-10
IL92632A0 (en) 1990-08-31
NO176476C (no) 1995-04-12
ATE100086T1 (de) 1994-01-15
IE893987L (en) 1990-06-14
HU910647D0 (en) 1991-09-30
NO176476B (no) 1995-01-02
FI895925A0 (sv) 1989-12-12
DK630489A (da) 1990-06-15
HU896603D0 (en) 1990-02-28
JPH02258766A (ja) 1990-10-19
CN1032203C (zh) 1996-07-03
NO894814D0 (no) 1989-12-01
HUT59907A (en) 1992-07-28
HU210056B (en) 1995-01-30
JP2954954B2 (ja) 1999-09-27
EP0373423B1 (de) 1994-01-12
CN1043501A (zh) 1990-07-04
PT92550A (pt) 1990-06-29
NO894814L (no) 1990-06-15
DE58906708D1 (de) 1994-02-24

Similar Documents

Publication Publication Date Title
FI92196B (sv) Förfarande för framställning av terapeutiskt användbara 2-pyridoner
FI93007B (sv) Förfarande för framställning av terapeutiskt användbara substituerade pyridiner samt i förfarandet användbara mellanprodukter
JPH06234741A (ja) 置換4−フエニルピリドン及び4−フエニル−2−アルコキシピリジン
US4992462A (en) Substituted pyrroles
FI92195B (sv) Förfarande för framställning av terapeutiskt användbara pyridinderivat
US4588732A (en) Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4968681A (en) Substituted hydroxylamines
US5093363A (en) 2,4,6-substituted phenol derivatives
US5034399A (en) Substituted 1,8-naphthyridines and their use in medicaments
KR890002640B1 (ko) 치환된 이미다조[1, 5-a]피리딘의 제조방법
AU622342B2 (en) Imino-substituted pyridines
JPH02247179A (ja) ピリド(2,3―d)ピリミジン類、その製法および用途
US5138090A (en) Substituted biphenyls
US5164506A (en) Substituted 2-pyridones and pyrid-2-thiones compounds
AU637632B2 (en) Substituted amino-pyridines
US4539410A (en) N-Substituted-2-(1-imidazolyl)indoles
AU630390B2 (en) Substituted 2-pyridones and pyrid-2-thiones, processes for their preparation and their use in medicaments
US4346099A (en) Carboxy-imidazole derivatives, compositions and use
US5183897A (en) Certain intermediate imino-substituted pyridines
JPH07173120A (ja) 置換芳香族カルボン酸誘導体
JPS622586B2 (sv)

Legal Events

Date Code Title Description
FG Patent granted

Owner name: BAYER AKTIENGESELLSCHAFT

BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: BAYER AKTIENGESELLSCHAFT